Adaptimmune Therapeutics plc (ADR)
General ticker "ADAP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $83.5M (TTM average)
Adaptimmune Therapeutics plc (ADR) does not follow the US Stock Market performance with the rate: -19.1%.
Estimated limits based on current volatility of 16.6%: low 0.03$, high 0.04$
Factors to consider:
- Total employees count: 449 (-15.9%) as of 2023
- Top business risk factors: Market volatility, Dependency on third parties, Supply chain disruptions, Economic downturns and volatility, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.38$, 1.17$]
- 2025-12-31 to 2026-12-31 estimated range: [0.46$, 1.32$]
Financial Metrics affecting the ADAP estimates:
- Positive: with PPE of -2.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -49.95 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 4.82 <= 18.93
- Positive: Interest expense per share per price, % of 2.28 <= 3.41
- Negative: negative Net income
Short-term ADAP quotes
Long-term ADAP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $27.15MM | $60.28MM | $178.03MM |
| Operating Expenses | $191.11MM | $200.02MM | $246.79MM |
| Operating Income | $-163.97MM | $-139.74MM | $-68.76MM |
| Non-Operating Income | $1.01MM | $27.21MM | $1.49MM |
| Interest Expense | $0.00MM | $0.00MM | $3.35MM |
| R&D Expense | $127.73MM | $126.51MM | $149.06MM |
| Income(Loss) | $-162.96MM | $-112.53MM | $-67.27MM |
| Taxes | $2.50MM | $1.34MM | $3.58MM |
| Profit(Loss)* | $-165.46MM | $-113.87MM | $-70.81MM |
| Stockholders Equity | $81.88MM | $39.51MM | $11.85MM |
| Inventory | $0.00MM | $0.00MM | $7.32MM |
| Assets | $328.92MM | $282.62MM | $245.96MM |
| Operating Cash Flow | $-141.77MM | $-140.88MM | $-73.21MM |
| Capital expenditure | $29.74MM | $4.88MM | $2.72MM |
| Investing Cash Flow | $89.14MM | $176.54MM | $-58.95MM |
| Financing Cash Flow | $12.87MM | $0.88MM | $78.75MM |
| Earnings Per Share** | $-1.03 | $-0.57 | $-0.28 |
| Ordinary share to ADR | 0.17x | 0.17x | 0.17x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.